**HIGHLY SPECIALISED TECHNOLOGIES PROGRAMME**

**Equality impact assessment – Scoping**

**HST: Elosulfase alfa for treating mucopolysaccharidosis type IVA**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

   None identified

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

   Not applicable

3. Has any change to the draft scope been agreed to highlight potential equality issues?

   Not applicable

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

   Not applicable

---

**Approved by Associate Director (name):** Josie Godfrey

**Date:** 29/09/14

Highly Specialised Technologies: Scoping
Equality impact assessment for the highly specialised technology evaluation of elosulfase alfa for treating mucopolysaccharidosis type IVA

Issue date: October 2014